

POLARIS QCDR IN COLLABORATION WITH THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) – 2022 MEASURE SPECIFICATIONS

QOPI23

Measure #	QOPI23
Measure Title	Concurrent Chemo radiation for Patients with a Diagnosis of Stage IIIB NSCLC
Measure Description	Percentage of patients, regardless of age, with a diagnosis of Stage IIIB non-small cell lung cancer (NSCLC) receiving concurrent chemoradiation.
Denominator Exclusion	Superior sulcus cancers
Denominator Exceptions	Patients who received first line platinum-based chemotherapy and radiation on a clinical trial; Performance status is ECOG 3 or 4, or Karnofsky performance status is 10-40; Patient performance status is 3 / 40-50% / Bed time, greater than 50%; Patient performance status is 4 / 10-30% / Unable to get out of bed; Patients with medical contraindication for concurrent chemoradiation
Denominator	All patients, regardless of age, with Stage IIIB NSCLC at diagnosis (AJCC 8th Edition)
Numerator	Patients who received first-line platinum-based chemotherapy and radiation
Numerator Exclusions	None
Number of Performance Rates to be calculated and submitted	1
Inverse Status	No
Proportional, CV, Ratio Status	Proportional
Risk Adjusted, if applicable	No
High Priority measure	No
Measure type	Process
NQS Domain	Effective Clinical Care
NQF ID	N/A
Meaningful Measure Area	Patient-Focused Episode of Care
Care Setting (s)	Ambulatory Care: Clinician Office/Clinic
Telehealth, if applicable	No

Copyright: ©2021 American Society of Clinical Oncology. All Rights Reserved. The American Society for Clinical Oncology (ASCO) owns all rights, title, and interests in this quality measure. This quality measure is provided solely for the benefit of ASCO, its members and the Polaris Qualified Clinical Data Registry for the purposes specified herein and for other ASCO purposes. It may not be used by other parties except with prior written approval of ASCO. Contact measurement@asco.org for licensing this measure.